標(biāo)題: Titlebook: Immunotherapy; Aung Naing,Joud Hajjar Book Apr 20171st edition The Editor(s) (if applicable) and The Author(s), under exclusive license to [打印本頁(yè)] 作者: fallacy 時(shí)間: 2025-3-21 18:04
書(shū)目名稱Immunotherapy影響因子(影響力)
作者: 帶來(lái)的感覺(jué) 時(shí)間: 2025-3-21 22:32
Bettzy Stephen,Joud Hajjarford, 1962), the advantages of recording BP in natural settings have become firmly established. Compared to BP values obtained in a doctor’s office or clinic, 24-hr ambulatory BP measurements are less likely to give inflated estimates of an individual’s BP (Burstyn, O’Donovan, & Charlton, 1981; Flor作者: diathermy 時(shí)間: 2025-3-22 00:50 作者: 敵手 時(shí)間: 2025-3-22 07:09
Jonathan E. Schoenhals,Tijana Skrepnik M.D.,Ugur Selek M.D.,Maria A. Cortez Ph.D.,Ailin Li M.D., Ph.ars ago, the wise men of the East had learned to exert authority over a broad range of bodily experiences and functions using techniques that are still taught today. But it is only in the past few decades that the West has become aware once again of the range of control that the central nervous syst作者: 沙發(fā) 時(shí)間: 2025-3-22 11:36
Lucia Masarova,Hagop Kantarjian,Guillermo Garcia-Mannero,Farhad Ravandi,Padmanee Sharma,Naval Daverars ago, the wise men of the East had learned to exert authority over a broad range of bodily experiences and functions using techniques that are still taught today. But it is only in the past few decades that the West has become aware once again of the range of control that the central nervous syst作者: Minutes 時(shí)間: 2025-3-22 16:57 作者: LANCE 時(shí)間: 2025-3-22 19:21 作者: Laconic 時(shí)間: 2025-3-22 22:02
Yousra Eleneen M.B.B.Ch.,Rivka R. Colen M.D.the field of infec- fense mechanisms and the characterization of the genetic tious diseases during the last decades of the previous mutations involved, with the prospect of novel strategies century. The paradigm of the immunocompromised host for therapeutic interventions and possible corrective gene作者: Contort 時(shí)間: 2025-3-23 01:23 作者: 保全 時(shí)間: 2025-3-23 07:18 作者: 宿醉 時(shí)間: 2025-3-23 11:52
Overview of Basic Immunology for Clinical Investigators,cludes macrophages, dendritic cells, natural killer cells, neutrophils, mast cells, B cells, and T cells are found in the core, the invasive margin, or the adjacent stromal or lymphoid component of the tumor. The immune infiltrate is heterogeneous and varies within a patient and between patients of 作者: 挑剔小責(zé) 時(shí)間: 2025-3-23 14:49 作者: FLOUR 時(shí)間: 2025-3-23 20:46 作者: 挑剔小責(zé) 時(shí)間: 2025-3-23 23:50
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for gnostic factors, older age, or relapsed disease. The last decade has seen a surge in successful immune-based therapies in various solid tumors; however, the role of immune therapies in AML remains poorly defined. This chapter describes the rationale, clinical data, and toxicity profiles of immune-ba作者: Spartan 時(shí)間: 2025-3-24 05:07
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon,than 20% for all the newly diagnosed patients. Cisplatin-based cytotoxic chemotherapy for unresectable or metastatic NSCLC patients in the first line of treatment, and docetaxel in the second line, have achieved positive results but with limited benefit in overall survival. Targeted therapies for EG作者: Ornament 時(shí)間: 2025-3-24 06:47 作者: 監(jiān)禁 時(shí)間: 2025-3-24 13:38
Cancer Imaging in Immunotherapy, those typically seen with conventional cytotoxic therapies. In fact, only 10% of patients on immunotherapy may show tumor shrinkage, typical of positive responses on conventional therapy. Conversely, those on immune therapies may initially demonstrate a delayed response, transient enlargement follo作者: 創(chuàng)新 時(shí)間: 2025-3-24 16:28 作者: 輕快走過(guò) 時(shí)間: 2025-3-24 21:53 作者: forager 時(shí)間: 2025-3-25 02:14
Overview of Basic Immunology for Clinical Investigators,lls and their role in tumor immune surveillance is of paramount importance to identify immune targets and to develop novel immune therapeutics in the war against cancer. In this chapter, we provide an overview of the individual components of the human immune system and the translational relevance of predictive biomarkers.作者: Antecedent 時(shí)間: 2025-3-25 05:17
Cancer Imaging in Immunotherapy,therapies including immunotherapies still relies on the current RECIST criteria. In this review, we review the traditional and new imaging response criteria for evaluation of solid tumors and briefly touch on some of the more commonly associated immunotherapy-induced adverse events.作者: obstinate 時(shí)間: 2025-3-25 07:41
Book Apr 20171st editionnotherapeutic approaches currently in use and strategies to overcome the associated challenges. As comprehensive knowledge of basic immunology in the context of tumor biology is required to move further along the line of development in translational science, this book provides an overview of the cel作者: 愛(ài)花花兒憤怒 時(shí)間: 2025-3-25 13:35 作者: 哄騙 時(shí)間: 2025-3-25 19:09 作者: Iniquitous 時(shí)間: 2025-3-25 21:28
Skin Reactions to Immune Checkpoint Inhibitors,tantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat. In the following chapter, we will review the categories of these drugs, common cutaneous effects, their grading, and management options.作者: creditor 時(shí)間: 2025-3-26 03:42
https://doi.org/10.1007/978-3-319-53156-4Immunotherapy; Translational cancer immunology; Vaccine; IL-10; ImmunoOncology作者: FOVEA 時(shí)間: 2025-3-26 05:08
The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 高深莫測(cè) 時(shí)間: 2025-3-26 11:31
Aung Naing,Joud HajjarHighlights the significant developments in the field of immuno-oncology to inform the scientific community.Summarizes diverse immunotherapeutic approaches for management of cancer to update profession作者: 時(shí)代錯(cuò)誤 時(shí)間: 2025-3-26 14:37
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/i/image/462294.jpg作者: 陰謀小團(tuán)體 時(shí)間: 2025-3-26 18:05 作者: conifer 時(shí)間: 2025-3-27 00:16
Optimizing Radiotherapy with Immunotherapeutic Approaches,sing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized t作者: SOB 時(shí)間: 2025-3-27 02:26 作者: 攤位 時(shí)間: 2025-3-27 06:10 作者: Indent 時(shí)間: 2025-3-27 13:09
Immune Therapy for Sarcomas,es, natural killer (NK) cells, T cell receptor (TCR) and chimeric antigen receptor (CAR) T cells, and efforts to decrease inflammation. The latter is particularly important because of new knowledge about factors influencing expression of checkpoint inhibitory molecules, PD1 and CTLA-4, in the tumor 作者: insurgent 時(shí)間: 2025-3-27 17:34
0065-2598 management of cancer broadly classified as hematological malignancies, solid tumors, and tumors arising in the connective tissue. The book also discusses alternative formulations and combinatorial approaches to作者: Gerontology 時(shí)間: 2025-3-27 18:26
tini, Di Marco, Mormino, Fazio, Libardoni, Mos, Casiglia, & Dal, 1986). These advantages derive from the fact that the 50–100 readings typically obtained in a single 24-hr ambulatory recording yield a considerably more stable mean level of BP compared to the two or three readings obtained in an offi作者: CUB 時(shí)間: 2025-3-28 00:16 作者: 壕溝 時(shí)間: 2025-3-28 04:33 作者: 門(mén)窗的側(cè)柱 時(shí)間: 2025-3-28 09:39 作者: defibrillator 時(shí)間: 2025-3-28 13:03 作者: 憤慨點(diǎn)吧 時(shí)間: 2025-3-28 16:16 作者: Inelasticity 時(shí)間: 2025-3-28 18:59 作者: Rodent 時(shí)間: 2025-3-29 01:00 作者: Dri727 時(shí)間: 2025-3-29 04:49
Noha Abdel-Wahab M.D., Ph.D.,Anas Alshawa M.D.,Maria E. Suarez-Almazor M.D., Ph.D.he 1960s and subsequent decades, the clinical During life, there exist phases of age-related c- and immunological aspects of immune deficiencies were promised immune functions. After birth there is a phys- studied and adequate treatment attempted. A reflection of logical immune deficiency because th作者: 聯(lián)合 時(shí)間: 2025-3-29 07:57
